Sandoz【0SAN】銘柄情報

Sandoz Group AG (0SAN) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

( - )

買値

0.00

売値

0.00

出来高

285,320

平均取引量 (3 か月)

CHF 696,736

財務取引量

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

企業価値

42.922B

前日終値

0.00

始値

時刻

67.74102

(O)

最終取引時間

VWAP

歳入

11.16B

純利益

914M

発行済株式数

432,692,617

浮動株比率 (%)

95.76%

機関投資家保有比率 (%)

39.60%

配当利回り

1.01

PER

43.08

株価売上高倍率 (PSR)

3.49

1 株当たり利益 (EPS)

2.09

ベータ

0.5

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neu... Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. 詳細を表示

セクター

Health Care

業界

ウェブサイト

www.sandoz.com

本社

Basel, Switzerland

設立

1886

Sandoz Group AG is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0SAN. The last closing price for Sandoz was CHF0. Over the last year, Sandoz shares have traded in a share price range of CHF 0.00 to CHF 0.00.

Sandoz currently has 432,692,617 shares in issue. Sandoz has a price to earnings ratio (PE ratio) of 43.08.

European Stocks Decline, Extending Previous Session’s Losses: DAX, CAC, FTSE100

European equities moved lower on Wednesday, continuing the downward trend from the prior session after a report from the The Wall Street Journal...

DAX, CAC, FTSE100, European markets trade mixed as investors await a wave of central bank decisions

European equities delivered a mixed performance on Monday as traders positioned themselves ahead of a busy week packed with interest rate...

DAX, CAC, FTSE100, European Stocks Slip as AI Bubble Fears Weigh on Sentiment

European equity markets moved mostly lower on Monday, as renewed anxiety over a potential artificial-intelligence bubble and slowing global...

European markets mixed as U.S. extends tariff pause on China

European stocks posted another mixed performance on Tuesday after Washington extended its suspension of higher tariffs on Chinese goods until...

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations MEDIA RELEASE Sandoz signs 10-year...

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter Ad hoc announcement pursuant to art. 53 SIX Swiss...

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in...

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market...

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million...

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars MEDIA RELEASE Pyzchiva® first...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0SAN - Frequently Asked Questions (FAQ)

What is the current Sandoz Group AG share price?

The current share price of Sandoz Group AG is CHF 0.00

How many Sandoz Group AG shares are in issue?

Sandoz Group AG has 432,692,617 shares in issue

What is the 1 year trading range for Sandoz Group AG share price?

Sandoz Group AG has traded in the range of CHF 0.00 to CHF 0.00 during the past year

What is the PE ratio of Sandoz Group AG?

The price to earnings ratio of Sandoz Group AG is 43.08

What is the cash to sales ratio of Sandoz Group AG?

The cash to sales ratio of Sandoz Group AG is 3.49

What is the registered address of Sandoz Group AG?

The registered address for Sandoz Group AG is Centralbahnstrasse 4, Basel, Basel-Stadt, 4051

What is the Sandoz Group AG website address?

The website address for Sandoz Group AG is www.sandoz.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Sandoz Group AG について

0SAN 最新ニュース

European Stocks Decline, Extending Previous Session’s Losses: DAX, CAC, FTSE100

DAX, CAC, FTSE100, European markets trade mixed as investors await a wave of central bank decisions

DAX, CAC, FTSE100, European Stocks Slip as AI Bubble Fears Weigh on Sentiment

European markets mixed as U.S. extends tariff pause on China

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

0SAN - Frequently Asked Questions (FAQ)

0SAN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sandoz Group AG (0SAN)

Sandoz Group AG (0SAN) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Sandoz Group AG について

0SAN 最新ニュース

European Stocks Decline, Extending Previous Session’s Losses: DAX, CAC, FTSE100

DAX, CAC, FTSE100, European markets trade mixed as investors await a wave of central bank decisions

DAX, CAC, FTSE100, European Stocks Slip as AI Bubble Fears Weigh on Sentiment

European markets mixed as U.S. extends tariff pause on China

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz launches renewable energy partnership to cover nearly 90% of electricity demand for European operations

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France

0SAN - Frequently Asked Questions (FAQ)

0SAN 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE